MAIA Biotechnology, Inc. SEC filings MAIA
MAIA Biotechnology, Inc. has 503 filings in SEC EDGAR's recent list, going back to Oct 15, 2021. Its latest annual report, Form ARS, was filed on Apr 7, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 10, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 6, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 424B3 | Prospectus | Oct 7, 2026 | — |
| 424B3 | Prospectus | Oct 2, 2026 | — |
| S-3 | Shelf registration | Sep 25, 2026 | — |
| S-3 | Shelf registration | Aug 21, 2026 | — |
| 424B5 | Prospectus supplement | May 14, 2026 | — |
| S-8 | Employee stock plan registration | Apr 7, 2026 | — |
| 424B5 | Prospectus supplement | Mar 4, 2026 | — |
| 424B5 | Prospectus supplement | Mar 2, 2026 | — |
| S-8 | Employee stock plan registration | Mar 28, 2025 | — |
| 424B5 | Prospectus supplement | Mar 26, 2025 | — |
| 424B5 | Prospectus supplement | Dec 23, 2024 | — |
| 424B5 | Prospectus supplement | May 15, 2024 | — |
| S-8 | Employee stock plan registration | Apr 19, 2024 | — |
| 424B5 | Prospectus supplement | Mar 25, 2024 | — |
| 424B5 | Prospectus supplement | Feb 14, 2024 | — |
| 424B5 | Prospectus supplement | Nov 17, 2023 | — |
| 424B5 | Prospectus supplement | Nov 15, 2023 | — |
| 424B5 | Prospectus supplement | Sep 1, 2023 | — |
| S-3 | Shelf registration | Aug 15, 2023 | — |
| FWP | Free writing prospectus | Jul 11, 2023 | — |
| S-8 | Employee stock plan registration | Jun 30, 2023 | — |
| FWP | Free writing prospectus | Jun 9, 2023 | — |
| S-1 | Registration statement | Jun 8, 2023 | — |
| 424B3 | Prospectus | Apr 27, 2023 | — |
| 424B4 | Prospectus | Apr 26, 2023 | — |
| S-1/A | Amended registration statement | Apr 21, 2023 | — |
| FWP | Free writing prospectus | Apr 20, 2023 | — |
| S-1/A | Amended registration statement | Apr 20, 2023 | — |
| FWP | Free writing prospectus | Apr 18, 2023 | — |
| FWP | Free writing prospectus | Apr 11, 2023 | — |
| FWP | Free writing prospectus | Apr 7, 2023 | — |
| S-1/A | Amended registration statement | Apr 4, 2023 | — |
| FWP | Free writing prospectus | Feb 13, 2023 | — |
| S-1 | Registration statement | Feb 6, 2023 | — |
| S-8 | Employee stock plan registration | Aug 1, 2022 | — |
| 424B4 | Prospectus | Jul 29, 2022 | — |
| S-1/A | Amended registration statement | Jul 21, 2022 | — |
| FWP | Free writing prospectus | Jul 14, 2022 | — |
| S-1/A | Amended registration statement | Jul 13, 2022 | — |
| S-1/A | Amended registration statement | Jun 29, 2022 | — |
| S-1/A | Amended registration statement | May 31, 2022 | — |
| S-1/A | Amended registration statement | May 16, 2022 | — |
| S-1/A | Amended registration statement | Apr 29, 2022 | — |
| S-1 | Registration statement | Apr 11, 2022 | — |
Showing 44 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MAIA (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Chicago, IL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1878313
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.